CY1122580T1 - Χημικη συνθεση χρησιμη ως ενδιαμεσο για την παρασκευη ενος αναστολεα κατεχολ-ο-μεθυλοτρανσφερασης - Google Patents
Χημικη συνθεση χρησιμη ως ενδιαμεσο για την παρασκευη ενος αναστολεα κατεχολ-ο-μεθυλοτρανσφερασηςInfo
- Publication number
- CY1122580T1 CY1122580T1 CY20191101241T CY191101241T CY1122580T1 CY 1122580 T1 CY1122580 T1 CY 1122580T1 CY 20191101241 T CY20191101241 T CY 20191101241T CY 191101241 T CY191101241 T CY 191101241T CY 1122580 T1 CY1122580 T1 CY 1122580T1
- Authority
- CY
- Cyprus
- Prior art keywords
- catechol
- preparation
- methylotransfer
- inhibitor
- chemical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570141P | 2011-12-13 | 2011-12-13 | |
| GBGB1121413.7A GB201121413D0 (en) | 2011-12-13 | 2011-12-13 | Chemical compounds and processes |
| US201261593625P | 2012-02-01 | 2012-02-01 | |
| GBGB1201758.8A GB201201758D0 (en) | 2012-02-01 | 2012-02-01 | Chemical compounds and processes |
| US201261718589P | 2012-10-25 | 2012-10-25 | |
| PCT/PT2012/000048 WO2013089573A1 (en) | 2011-12-13 | 2012-12-12 | Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122580T1 true CY1122580T1 (el) | 2021-01-27 |
Family
ID=48612903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101241T CY1122580T1 (el) | 2011-12-13 | 2019-11-27 | Χημικη συνθεση χρησιμη ως ενδιαμεσο για την παρασκευη ενος αναστολεα κατεχολ-ο-μεθυλοτρανσφερασης |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9126988B2 (enExample) |
| EP (2) | EP2791134B1 (enExample) |
| JP (3) | JP6456143B2 (enExample) |
| BR (1) | BR112014014341A2 (enExample) |
| CA (2) | CA3088684C (enExample) |
| CY (1) | CY1122580T1 (enExample) |
| DK (1) | DK2791134T3 (enExample) |
| ES (2) | ES2960805T3 (enExample) |
| HR (1) | HRP20192133T8 (enExample) |
| HU (1) | HUE047856T2 (enExample) |
| PL (1) | PL2791134T3 (enExample) |
| PT (2) | PT3604299T (enExample) |
| RS (1) | RS59666B1 (enExample) |
| SI (1) | SI2791134T1 (enExample) |
| WO (1) | WO2013089573A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006272978B2 (en) | 2005-07-26 | 2012-06-07 | Bial - Portela & Ca, S.A. | Nitrocatechol derivatives as COMT inhibitors |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| CN101631548B (zh) | 2007-01-31 | 2014-08-27 | 比艾尔-坡特拉有限公司 | Comt抑制剂的单次药物剂量单元和药物组合物 |
| AU2009226221A1 (en) | 2008-03-17 | 2009-09-24 | Bial - Portela & Ca., S.A. | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol |
| KR102023255B1 (ko) | 2009-04-01 | 2019-09-19 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법 |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| BR112014014341A2 (pt) * | 2011-12-13 | 2017-08-22 | Bial Portela & Ca Sa | Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica |
| WO2016083863A1 (en) | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
| GB2563858A (en) * | 2017-06-27 | 2019-01-02 | Azad Pharmaceutical Ingredients Ag | New route of synthesis for opicapone |
| KR20200100075A (ko) * | 2017-12-18 | 2020-08-25 | 유니켐 레버러토리스 리미티드 | 오피카폰 및 그의 중간체의 제조방법 |
| WO2020072886A1 (en) | 2018-10-05 | 2020-04-09 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| EP3860602A1 (en) | 2018-10-05 | 2021-08-11 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| CN109529881A (zh) * | 2018-11-12 | 2019-03-29 | 刘晓菊 | 一种治疗帕金森药物用中间体5-硝基香草酸的制备方法 |
| CN120478288A (zh) * | 2020-03-13 | 2025-08-15 | 巴尔-波特拉及康邦亚股份有限公司 | 微粉化的奥匹卡朋 |
| TW202200138A (zh) * | 2020-05-26 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 包含奧匹卡朋（ｏｐｉｃａｐｏｎｅ）之錠劑 |
| GB202011709D0 (en) | 2020-07-28 | 2020-09-09 | Bial Portela & Ca Sa | Solid dispersion of opicapone |
| GB202016425D0 (en) | 2020-10-16 | 2020-12-02 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| CN112375014A (zh) * | 2020-12-17 | 2021-02-19 | 重庆柳江医药科技有限公司 | 一种奥匹卡朋工艺杂质及制备方法和用途 |
| WO2022131944A1 (en) | 2020-12-17 | 2022-06-23 | Bial-Portela & Ca., S.A. | Treatment regimens for early idiopathic parkinson's disease |
| US20240300930A1 (en) * | 2021-02-26 | 2024-09-12 | Msn Laboratories Private Limited, R&D Center | Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide |
| CN113292489B (zh) * | 2021-06-16 | 2022-08-30 | 泓博智源(开原)药业有限公司 | 二氯代二烷基烟腈的制备方法 |
| GB202204798D0 (en) | 2022-04-01 | 2022-05-18 | Bial Portela & Ca Sa | Prodrugs of opicapone |
| GB202212082D0 (en) | 2022-08-18 | 2022-10-05 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| GB202219669D0 (en) | 2022-12-23 | 2023-02-08 | Bial Portela & Ca Sa | Processes and intermediates for synthesising opicapone |
| WO2024242579A1 (en) | 2023-05-25 | 2024-11-28 | Bial-Portela & Ca., S.A. | Treatment regimens for early idiopathic parkinson's disease |
| EP4727649A1 (en) * | 2023-06-19 | 2026-04-22 | Medichem, S.A. | Process for preparing opicapone |
| WO2025012643A1 (en) | 2023-07-11 | 2025-01-16 | Tay Therapeutics Limited | Compounds comprising a naphthyridine or pyridopyrimidine core as ptc read-through agents |
| CN119775271A (zh) * | 2024-12-31 | 2025-04-08 | 南京海纳医药科技股份有限公司 | 一种奥吡卡朋粗品的精制方法 |
| CN120081837A (zh) * | 2025-02-14 | 2025-06-03 | 江苏天士力帝益药业有限公司 | 一种低单杂高纯度的奥匹卡朋中间体05的制备方法 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1532178A (en) | 1921-07-25 | 1925-04-07 | Louis A Godbold | Lubricator |
| FR1260080A (fr) | 1960-03-22 | 1961-05-05 | Materiel De Forage Soc De Fab | Trépan à molettes étanche |
| US3647809A (en) | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
| US4264573A (en) | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| US4386668A (en) | 1980-09-19 | 1983-06-07 | Hughes Tool Company | Sealed lubricated and air cooled rock bit bearing |
| DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
| US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| DE3840954A1 (de) | 1988-12-05 | 1990-06-07 | Shell Int Research | Herstellung von 2-chlornicotinsaeureestern |
| US5206372A (en) | 1990-06-05 | 1993-04-27 | Shell Research Limited | Preparation of 2-chloropyridine derivatives |
| ATE113202T1 (de) | 1990-11-29 | 1994-11-15 | Wei Ming Pharmaceutical Mfg Co | Hilfsträger für direkte verpressung. |
| EP0619814A1 (en) | 1991-12-31 | 1994-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
| FR2730322B1 (fr) | 1995-02-02 | 1997-04-30 | Imago | Monture de lunettes metallique |
| DE19628617A1 (de) | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
| US6206110B1 (en) | 1996-09-09 | 2001-03-27 | Smith International, Inc. | Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit |
| JP2002526482A (ja) | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｐ３８のインヒビター |
| GB2344819A (en) | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| CN1313465C (zh) | 1999-08-19 | 2007-05-02 | Nps药物有限公司 | 杂多环化合物及其用于制备代谢性谷氨酸受体拮抗剂的应用 |
| FI20000635A0 (fi) | 2000-03-17 | 2000-03-17 | Orion Yhtymae Oyj | COMT-inhibiittoreiden käyttö analgeettina |
| SE0001438D0 (sv) | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
| DE10029201A1 (de) | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
| GB2363792A (en) | 2000-06-21 | 2002-01-09 | Portela & Ca Sa | Nitrocatechols |
| CN1166626C (zh) | 2000-08-30 | 2004-09-15 | 李凌松 | 三或四取代苯基化合物、其制备方法及应用 |
| DK1356046T3 (da) | 2000-11-28 | 2010-03-01 | Zymogenetics L L C | Cytokinreceptor zcytoR19 |
| US20040097555A1 (en) | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
| EP1354603A1 (en) | 2000-12-26 | 2003-10-22 | Takeda Chemical Industries, Ltd. | Concomitant drugs |
| CA2438991C (en) | 2001-02-21 | 2010-08-17 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP1412327A2 (en) | 2001-05-30 | 2004-04-28 | LG Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
| CA2449544A1 (en) | 2001-06-08 | 2002-12-19 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs |
| BR0211358A (pt) | 2001-07-26 | 2004-09-21 | Merck Patent Gmbh | Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis |
| JP4379853B2 (ja) | 2001-10-05 | 2009-12-09 | 惠民製藥股▲分▼有限公司 | 直接錠剤化用調合物および補助剤の調合方法 |
| AU2003303373B8 (en) | 2002-12-18 | 2010-06-10 | Cytovia, Inc. | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| WO2005006945A2 (en) | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| AU2004263148B2 (en) | 2003-08-06 | 2008-08-21 | Vertex Pharmaceuticals, Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
| DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| US7300406B2 (en) | 2003-09-30 | 2007-11-27 | Carter Vandette B | Medical examination apparatus |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| JP2007535551A (ja) | 2004-04-28 | 2007-12-06 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｒｏｃｋおよび他のプロテインキナーゼの阻害剤として有用な組成物 |
| GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| JP2008519811A (ja) | 2004-11-10 | 2008-06-12 | オリオン コーポレーション | 下肢静止不能症候群の治療 |
| WO2006061697A1 (en) | 2004-12-06 | 2006-06-15 | Themis Laboratories Private Limited | Sulfonylurea compositions and a process for its preparation |
| US20080051441A1 (en) | 2004-12-28 | 2008-02-28 | Astrazeneca Ab | Aryl Sulphonamide Modulators |
| EP1833804A1 (en) | 2004-12-28 | 2007-09-19 | AstraZeneca AB | Aryl sulphonamide modulators |
| WO2006114400A1 (en) | 2005-04-26 | 2006-11-02 | Neurosearch A/S | Novel oxadiazole derivatives and their medical use |
| US20060257473A1 (en) | 2005-05-11 | 2006-11-16 | Porranee Puranajoti | Extended release tablet |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| WO2006132914A2 (en) | 2005-06-03 | 2006-12-14 | Abbott Laboratories | Cyclobutyl amine derivatives |
| JP2007024970A (ja) | 2005-07-12 | 2007-02-01 | Miyakawa:Kk | 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置 |
| US20090000437A1 (en) | 2005-07-14 | 2009-01-01 | Provo Craft And Novelty, Inc. | Methods for Cutting |
| AU2006272978B2 (en) | 2005-07-26 | 2012-06-07 | Bial - Portela & Ca, S.A. | Nitrocatechol derivatives as COMT inhibitors |
| FR2889525A1 (fr) | 2005-08-04 | 2007-02-09 | Palumed Sa | Nouveaux derives de polyquinoleines et leur utilisation therapeutique. |
| US20070048384A1 (en) | 2005-08-26 | 2007-03-01 | Joerg Rosenberg | Pharmaceutical compositions |
| EP1954137A4 (en) | 2005-11-18 | 2008-12-17 | Janssen Pharmaceutica Nv | 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE |
| EP1956013B1 (en) | 2005-11-30 | 2016-04-13 | Fujifilm RI Pharma Co., Ltd. | Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition |
| GB0606774D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
| EP1845097A1 (en) * | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| PE20080906A1 (es) | 2006-08-17 | 2008-07-05 | Kemia Inc | Derivados heteroarilo como inhibidores de citocina |
| US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| CN101631548B (zh) * | 2007-01-31 | 2014-08-27 | 比艾尔-坡特拉有限公司 | Comt抑制剂的单次药物剂量单元和药物组合物 |
| ES2663517T3 (es) | 2007-08-27 | 2018-04-13 | Dart Neuroscience (Cayman) Ltd | Compuestos terapéuticos de isoxazol |
| EP2259777A2 (en) | 2008-02-28 | 2010-12-15 | BIAL - Portela & Ca., S.A. | Pharmaceutical composition for poorly soluble drugs |
| AU2009226221A1 (en) | 2008-03-17 | 2009-09-24 | Bial - Portela & Ca., S.A. | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol |
| ES2723729T3 (es) | 2008-07-29 | 2019-08-30 | Bial Portela & Ca Sa | Régimen de administración de nitrocatecoles |
| KR102023255B1 (ko) | 2009-04-01 | 2019-09-19 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법 |
| JP5864410B2 (ja) | 2009-04-01 | 2016-02-17 | ノヴィファーマ ソシエテ アノニム | ニトロカテコール誘導体を含む医薬製剤及びその製造方法 |
| KR101868326B1 (ko) | 2010-03-04 | 2018-06-19 | 오리온 코포레이션 | 파킨슨병의 치료를 위한 레보도파, 카르비도파 및 엔타카폰의 용도 |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| BR112014014341A2 (pt) * | 2011-12-13 | 2017-08-22 | Bial Portela & Ca Sa | Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica |
-
2012
- 2012-12-12 BR BR112014014341A patent/BR112014014341A2/pt not_active Application Discontinuation
- 2012-12-12 EP EP12806720.4A patent/EP2791134B1/en active Active
- 2012-12-12 JP JP2014547135A patent/JP6456143B2/ja active Active
- 2012-12-12 DK DK12806720T patent/DK2791134T3/da active
- 2012-12-12 ES ES19194756T patent/ES2960805T3/es active Active
- 2012-12-12 WO PCT/PT2012/000048 patent/WO2013089573A1/en not_active Ceased
- 2012-12-12 US US14/365,265 patent/US9126988B2/en active Active
- 2012-12-12 PL PL12806720T patent/PL2791134T3/pl unknown
- 2012-12-12 PT PT191947563T patent/PT3604299T/pt unknown
- 2012-12-12 PT PT128067204T patent/PT2791134T/pt unknown
- 2012-12-12 ES ES12806720T patent/ES2758659T3/es active Active
- 2012-12-12 EP EP19194756.3A patent/EP3604299B1/en active Active
- 2012-12-12 RS RS20191562A patent/RS59666B1/sr unknown
- 2012-12-12 HR HRP20192133TT patent/HRP20192133T8/hr unknown
- 2012-12-12 CA CA3088684A patent/CA3088684C/en active Active
- 2012-12-12 SI SI201231703T patent/SI2791134T1/sl unknown
- 2012-12-12 HU HUE12806720A patent/HUE047856T2/hu unknown
- 2012-12-12 CA CA2858025A patent/CA2858025C/en active Active
-
2015
- 2015-07-31 US US14/814,603 patent/US9630955B2/en active Active
-
2017
- 2017-10-27 JP JP2017207738A patent/JP6721558B2/ja active Active
-
2019
- 2019-11-27 CY CY20191101241T patent/CY1122580T1/el unknown
- 2019-11-27 JP JP2019214566A patent/JP2020059729A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014014341A2 (pt) | 2017-08-22 |
| CA2858025A1 (en) | 2013-06-20 |
| EP3604299B1 (en) | 2023-07-26 |
| PT3604299T (pt) | 2023-10-31 |
| JP2015500335A (ja) | 2015-01-05 |
| EP2791134A1 (en) | 2014-10-22 |
| JP2020059729A (ja) | 2020-04-16 |
| ES2758659T3 (es) | 2020-05-06 |
| PL2791134T3 (pl) | 2020-03-31 |
| JP6456143B2 (ja) | 2019-01-23 |
| ES2960805T3 (es) | 2024-03-06 |
| SI2791134T1 (sl) | 2020-01-31 |
| RS59666B1 (sr) | 2020-01-31 |
| HUE047856T2 (hu) | 2020-05-28 |
| US9126988B2 (en) | 2015-09-08 |
| PT2791134T (pt) | 2019-12-18 |
| CA3088684C (en) | 2021-10-26 |
| CA3088684A1 (en) | 2013-06-20 |
| US9630955B2 (en) | 2017-04-25 |
| EP3604299A1 (en) | 2020-02-05 |
| HRP20192133T1 (hr) | 2020-02-21 |
| JP6721558B2 (ja) | 2020-07-15 |
| WO2013089573A1 (en) | 2013-06-20 |
| CA2858025C (en) | 2020-09-22 |
| JP2018052949A (ja) | 2018-04-05 |
| EP2791134B1 (en) | 2019-09-25 |
| US20160009700A1 (en) | 2016-01-14 |
| DK2791134T3 (da) | 2019-12-09 |
| HRP20192133T8 (hr) | 2021-02-19 |
| US20140350057A1 (en) | 2014-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014019049A2 (pt) | adenovirus imunogênico | |
| CR20110318A (es) | Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos | |
| CY1121997T1 (el) | Κρυσταλλικες μορφες του 2-((4s)-6-(4-χλωροφαινυλ)-1-μεθυλ-4η-βενζο[c]ισοξαζολo[4,5-ε]αζεπιν-4-υλ)ακεταμιδιου | |
| SV2011004019A (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
| BRPI0916769A2 (pt) | derivados de benzilbenzeno deuterados e métodos de uso | |
| PT2567707T (pt) | Composição de péptidos associados a tumores e vacina anticancro relacionada | |
| CR20140388A (es) | Compuestos terapeuticamente activos y sus métodos de uso | |
| CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
| PT2478000T (pt) | Evento transgénico mon 87708 de soja e métodos de sua utilização | |
| SV2009003098A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
| HRP20160551T8 (hr) | Kombinirana terapija s pripravcima nanočestica taksana i hedgehog inhibitora | |
| CL2012001405A1 (es) | Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer. | |
| UY32456A (es) | Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento | |
| GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
| MX2011009690A (es) | Métodos y composiciones para trastornos relacionados con la proliferación celurar. | |
| EP2827869A4 (en) | COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGUE THEREOF, WITH MEISOINDIGO | |
| UY34278A (es) | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades | |
| EA201070237A1 (ru) | Четвертичные опиоидные карбоксамиды | |
| BRPI1013698A2 (pt) | métodos para tratamento com o uso de terapia de combinação | |
| ECSP109903A (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
| BR112013020767A2 (pt) | composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo | |
| PL2632452T3 (pl) | Związki i kompozycje stosowane w leczeniu nowotworów | |
| BR112015029386A8 (pt) | uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit | |
| BR112015025709A2 (pt) | monoterapia com gla para uso em tratamento de câncer | |
| PL2152256T3 (pl) | Związki aktywujące telomerazę i sposoby ich zastosowania |